Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT01349049 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: PLX3397
DRUG: PLX3397

Sponsor

Daiichi Sankyo

Collaborators

[object Object]